Association of trabecular bone score and bone mineral apparent density with the severity of bone fragility in children and adolescents with osteogenesis imperfecta: A cross-sectional study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
02
2023
accepted:
16
08
2023
medline:
31
8
2023
pubmed:
29
8
2023
entrez:
29
8
2023
Statut:
epublish
Résumé
Osteogenesis imperfecta (OI) is a hereditary skeletal disease characterized by bone fragility. Areal bone mineral density (BMD), evaluated by dual-energy X-ray absorptiometry (DXA), is used to assess bone brittleness. The height-adjusted BMD Z-score (BMDHAZ) is calculated in children and adolescents with OI to reduce the confounding factor of short stature. However, even with the BMDHAZ, severity evaluation in children and adolescents with OI is challenging because certain abnormalities in bone quality cannot be accurately assessed by BMD analysis. The trabecular bone scores (TBS) and bone mineral apparent density (BMAD), which represent the structural integrity of bone and bone-size-associated BMD, respectively, are associated with fracture risk. Recently, age- and sex-specific reference ranges have been reported, enabling the calculation of Z-scores for children. To evaluate which density measurements show the highest correlation with fracture risk, we analyzed the associations between the Z-scores of TBS, BMAD, and BMDHAZ, fracture rate, and genetic variants. We retrospectively reviewed 42 participants with OI aged 5 to 20 years who underwent DXA. COL1A1/2 pathogenic variants were detected in 41 of the 42 participants. In participants with nonsense and frameshift variants (n = 17) resulting in haploinsufficiency and mild phenotype, the TBS Z-score was negatively correlated with fracture rate (FR) (r = -0.50, p = 0.042). In participants with glycine substitution (n = 9) causing the severe phenotype, the BMAD Z-scores were negatively correlated with FR (r = -0.74, p = 0.022). No correlation between the BMDHAZ and FR was observed in both groups. These findings suggest that the TBS and BMAD are useful in assessing children and adolescents with OI with specific genetic variants.
Identifiants
pubmed: 37643181
doi: 10.1371/journal.pone.0290812
pii: PONE-D-23-03588
pmc: PMC10464990
doi:
Substances chimiques
Minerals
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0290812Informations de copyright
Copyright: © 2023 Ohata et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nat Rev Endocrinol. 2011 Jun 14;7(9):540-57
pubmed: 21670757
J Bone Miner Res. 2022 Apr;37(4):776-785
pubmed: 35118727
J Med Genet. 1979 Apr;16(2):101-16
pubmed: 458828
Calcif Tissue Int. 1998 Jan;62(1):17-20
pubmed: 9405727
Arch Osteoporos. 2023 Jun 15;18(1):82
pubmed: 37318639
Best Pract Res Clin Rheumatol. 2008 Mar;22(1):85-100
pubmed: 18328983
Bone. 2005 Nov;37(5):634-41
pubmed: 16112635
Hum Mutat. 2007 Mar;28(3):209-21
pubmed: 17078022
Bone. 2014 Aug;65:18-24
pubmed: 24803077
J Cachexia Sarcopenia Muscle. 2021 Aug;12(4):1024-1033
pubmed: 34184837
J Clin Densitom. 2015 Jul-Sep;18(3):309-30
pubmed: 26277849
Connect Tissue Res. 2007;48(2):70-5
pubmed: 17453908
Osteoporos Int. 2015 Oct;26(10):2431-40
pubmed: 25956285
J Clin Densitom. 2014 Apr-Jun;17(2):258-74
pubmed: 24792821
J Bone Miner Res. 2013 Jan;28(1):206-12
pubmed: 22887693
JBMR Plus. 2019 Jan 07;3(5):e10118
pubmed: 31131341
J Clin Densitom. 2013 Jul-Sep;16(3):287-296
pubmed: 22749406
Osteoporos Int. 2013 Sep;24(9):2455-60
pubmed: 23468074
J Bone Miner Res. 1992 Feb;7(2):137-45
pubmed: 1570758
Bone. 2012 Nov;51(5):920-8
pubmed: 22910579
Bone. 2021 Feb;143:115608
pubmed: 32829035
Clin Pediatr Endocrinol. 2016 Apr;25(2):71-6
pubmed: 27212799
Calcif Tissue Int. 2013 Nov;93(5):453-61
pubmed: 23929220
J Clin Densitom. 2014 Apr-Jun;17(2):225-42
pubmed: 24690232
Endocr Rev. 2022 Jan 12;43(1):61-90
pubmed: 34007986
J Bone Miner Res. 2010 Jun;25(6):1367-74
pubmed: 19929435
Am J Med Genet A. 2019 Dec;179(12):2393-2419
pubmed: 31633310
J Clin Densitom. 2011 Jul-Sep;14(3):302-12
pubmed: 21724435
Clin Biomech (Bristol, Avon). 2013 Jan;28(1):110-6
pubmed: 23141422
Am J Hum Genet. 1996 Oct;59(4):799-809
pubmed: 8808594
J Pediatr Endocrinol Metab. 2016 Jul 1;29(7):813-8
pubmed: 27089405
Bone. 2020 Aug;137:115454
pubmed: 32464275
Bone. 2019 Sep;126:11-17
pubmed: 31039433
J Bone Miner Res. 2014 Mar;29(3):518-30
pubmed: 24443324
J Clin Endocrinol Metab. 2010 Mar;95(3):1265-73
pubmed: 20103654
J Bone Miner Res. 2017 Jan;32(1):172-180
pubmed: 27490028
Curr Osteoporos Rep. 2013 Jun;11(2):147-55
pubmed: 23504496
Osteoporos Int. 2020 Jun;31(6):1185
pubmed: 32246166
Bone. 2012 Jun;50(6):1317-23
pubmed: 22449447
Lancet. 2016 Apr 16;387(10028):1657-71
pubmed: 26542481
Arq Bras Endocrinol Metabol. 2010 Mar;54(2):87-98
pubmed: 20485895
Osteoporos Int. 2003 Sep;14 Suppl 5:S118-27
pubmed: 14504716
J Clin Endocrinol Metab. 2019 Apr 1;104(4):1283-1292
pubmed: 30265344
J Mech Behav Biomed Mater. 2015 Jun;46:261-70
pubmed: 25828157
Lancet. 2004 Apr 24;363(9418):1377-85
pubmed: 15110498
J Clin Densitom. 2019 Apr - Jun;22(2):229-235
pubmed: 30309730
Ther Adv Musculoskelet Dis. 2020 Nov 2;12:1759720X20969262
pubmed: 33224280
J Clin Endocrinol Metab. 2011 Oct;96(10):3160-9
pubmed: 21917867
Calcif Tissue Int. 1999 Aug;65(2):129-32
pubmed: 10430645